Addex Therapeutics Ltd (ADXN) Directors and Executive Officers

Officers & Directors

Tim Dyer, aged 57, is Chief Executive Officer and Director of Addex. He co-founded the company in 2002 and has over 20 years of leadership experience in life sciences, including finance and corporate development. He led Addex's initial public offering and Nasdaq listing. Dyer also served as CEO and CFO of Neurosterix until May 2025. He is a UK Chartered Accountant and holds a BSc (Hons) in Biochemistry and Pharmacology from the University of Southampton. Roger Mills, aged 69, is Chief Medical Officer and Director. He has over 30 years of experience in the biopharmaceutical industry, having worked with Acadia Pharmaceuticals, Pfizer, and Gilead Sciences. At Acadia Pharmaceuticals, he was Executive Vice President, Development and Chief Medical Officer, overseeing a major Phase 3 program and NDA submission for NUPLAZID. Mills is an Honorary Professor at the University of Exeter and a Fellow of the Faculty of Pharmaceutical Medicine. He holds a medical degree from Imperial College, Charing Cross Hospital Medical School, London. Mikhail Kalinichev, aged 58, is Head of Translational Science. He serves under a service agreement between Addex and Neurosterix and rejoined Addex in August 2021. His previous roles include positions at Addex, Ipsen, Lundbeck, and GlaxoSmithKline, focusing on neuroscience therapeutic strategy and translational studies. Lénaïc Teyssédou, aged 40, is Head of Finance. No additional background information is provided.

Addex Therapeutics Ltd currently has 17 employees.